BARCELONA—The finding from the phase-III ARCON trial presented at the 3rd ESTRO Forum that: Accelerated radiotherapy with carbogen and nicotinamide (ARCON) significantly improved outcomes for patients with advanced laryngeal cancer, was discussed with Oncology Times reporter Sarah Maxwell by Hans Kaanders PhD MD, from Radboud University Medical Centre.